"Tisch Cancer Institute Receives NCI Cancer Center Designation"
The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai has been named a National Cancer Institute cancer center. "The NCI designation recognizes our deep commitment to advance the field of cancer research, treatment, and prevention, and to bring these innovations to cancer patients and their families," TCI Director Steven Burakoff said in a statement. Mount Sinai President and CEO Kenneth Davis noted that among the institute's strengths that were "central to our NCI designation" was TCI's research, based on New York's diverse ethnic communities, into the genetic differences and disparities in care that result in greater cancer risk for some patients. Learn more.
Mount Sinai Researchers Engineer Rare Immune Cells to Create Powerful New Cancer Vaccine
Jul 21, 2025 View All Press Releases
Mount Sinai Study Advances Understanding of Personalized Vaccines for Bladder Cancer
May 12, 2025 View All Press Releases
Mount Sinai Researchers Discover How Melanoma May Spread to the Brain
Apr 30, 2025 View All Press Releases
Mount Sinai Showcases Innovative Cancer Research at 2025 AACR Annual Meeting in Chicago
Apr 24, 2025 View All Press Releases
Mount Sinai Leads Phase 3 Trial in Myelofibrosis Treatment
Mar 19, 2025 View All Press Releases